Product Description
"
Cobimetinib (GDC-0973, XL-518, Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It was studied in combination with vemurafenib, a BRAF inhibitor, to treat several cancers.
In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib
"
![1138028-44-0,(Z)-2-((Z)-2-((((((1R,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methyl)sulfonyl)oxy)imino)thiophen-3(2H)-ylidene)-2-(o-tolyl)acetonitrile](https://www.pudeepharm.com/wp-content/uploads/2025/12/400.jpg)
![2376639-48-2,Ethanesulfonicacid,1,1,2,2-tetrafluoro-2-(1,1,2,2-tetrafluoro-4-tricyclo[3.3.1.13,7]dec-1-ylbutoxy)-](https://www.pudeepharm.com/wp-content/uploads/2025/12/482.jpg)
![1383380-44-6,[1]Benzothieno[3,2-b][1]benzothiophene, 3,8-dibromo-](https://www.pudeepharm.com/wp-content/uploads/2025/12/446.jpg)
![1202575-36-7,3-Ethoxy-3-[4-(2-methyl-benzyloxy)-phenyl]-propionic acid](https://www.pudeepharm.com/wp-content/uploads/2025/12/3677.jpg)